GlassScriptPhysician profile
Sheila Rice
NPI 1023106473
$11,807.39
in general payments reported to CMS, 2019-2025
44 companies · $3,014 in 2025
The $3,014 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $1,080 · 2021: $346 · 2022: $1,020 · 2023: $2,224 · 2024: $2,598 · 2025: $3,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,836.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,162.97 | 2019-2025 | |
| Novo Nordisk INC | $1,085.05 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $937.71 | 2019-2025 | Evenity, Repatha, Repatha |
| Pfizer INC. | $915.71 | 2019-2025 | |
| Lilly USA, LLC | $819.18 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $642.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Corcept Therapeutics | $547.98 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $545.60 | 2019-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $440.54 | 2023-2025 | Auvelity, Symbravo |
| Janssen Pharmaceuticals, INC | $430.05 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $401.96 | 2019-2025 | Ajovy, Austedo Xr |
| Glaxosmithkline, LLC. | $266.17 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $247.05 | 2019-2024 | Jynarque, Rexulti |
| Antares Pharma, INC. | $204.17 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $183.00 | 2021-2025 | Freestyle Libre 2 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $174.68 | 2019-2024 | Trintellix, Vyvanse |
| Lupin INC. | $161.44 | 2019 | |
| Exact Sciences Corporation | $155.19 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $151.94 | 2023-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.89 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $130.02 | 2019-2023 | |
| Allergan, INC. | $125.04 | 2020 | |
| Dexcom, INC. | $101.87 | 2023-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $83.77 | 2019-2020 | |
| Sanofi Pasteur INC. | $82.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $76.57 | 2020-2024 | Gardasil, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $68.71 | 2019-2023 | |
| Ibsa Pharma INC. | $67.06 | 2019-2023 | Tirosint, Licart |
| Ardelyx, INC. | $64.55 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.46 | 2019-2023 | Jardiance |
| Acadia Pharmaceuticals INC | $37.41 | 2024-2025 | Daybue |
| Dynavax Technologies Corporation | $37.39 | 2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $36.26 | 2022 | |
| Corium, LLC | $34.95 | 2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $32.25 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $27.77 | 2023 | Contrave, Onzetra Xsail |
| Lundbeck LLC | $21.85 | 2024 | Vyepti |
| Organon LLC | $19.53 | 2025 | Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $18.28 | 2023 | Eliquis |
| Optinose US, INC. | $18.15 | 2024 | |
| Avanir Pharmaceuticals, INC. | $17.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.10 | 2025 | Zoryve |
| Amneal Pharmaceuticals LLC | $15.85 | 2025 | Unithroid |
| Therapeuticsmd, INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.